Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …

Background Paxlovid was granted an Emergency Use Authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …

SARS-CoV-2 is associated with broad tissue tropism, a characteristic often determined by
the availability of entry receptors on host cells. Here, we show that TMEM106B, a lysosomal …

Despite the need for novel, effective therapeutics for the COVID-19 pandemic, no curative
regimen is yet available, therefore patients are forced to rely on supportive and nonspecific …

Summary Background Nirmatrelvir plus ritonavir (Paxlovid) reduced the risk of
hospitalization or death by 89% in high-risk, ambulatory adults with COVID-19. We aimed at …

Numerous variants of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
pandemic have evolved. Viral variants may evolve with harmful susceptibility to the immunity …

The SARS-CoV-2 Omicron (B. 1.1529) variant was designated as a variant of concern (VOC)
by the World Health Organization (WHO) on November 26, 2021. Within two months, it had …

The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …

The US FDA approval of PAXLOVID, a combination therapy of nirmatrelvir and ritonavir has
significantly boosted our morale in fighting the COVID-19 pandemic. Nirmatrelvir is an …